Press release
Atherosclerosis Pipeline Assessment 2024: Therapies, Clinical Trials, and Emerging Therapies by DelveInsight | Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen
"Atherosclerosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atherosclerosis Market.
The Atherosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Atherosclerosis Pipeline Report: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Atherosclerosis treatment therapies with a considerable amount of success over the years.
• Atherosclerosis companies working in the treatment market are ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, CSL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others, are developing therapies for the Atherosclerosis treatment
• Emerging Atherosclerosis therapies in the different phases of clinical trials are- TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, and others are expected to have a significant impact on the Atherosclerosis market in the coming years.
• In April 2024, Bitterroot Bio has initiated a Phase I trial by dosing the first participants to evaluate its candidate for atherosclerotic cardiovascular disease treatment. The study involves healthy volunteers receiving subcutaneous doses of BRB-002, the company's cardio-immunology therapeutic candidate.
Atherosclerosis Overview
Atherosclerosis is a condition where the arteries become narrowed and hardened due to a buildup of plaque. Plaque is made up of fatty substances, cholesterol, cellular waste products, calcium, and fibrin (a clotting material) that accumulate in the inner lining of arteries. Over time, this buildup can restrict blood flow to organs and tissues throughout the body.
Get a Free Sample PDF Report to know more about Atherosclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Atherosclerosis Drugs Under Different Phases of Clinical Development Include:
• TATX-21: ImmunoPrecise Antibodies
• Epeleuton: Afimmune
• VERVE-101: Verve Therapeutics
• SLN360: Silence Therapeutics
• MK-0616: Merck Sharp & Dohme LLC
• REG-001: Regio Bioscience
• Olpasiran: Amgen
• Ziltivekimab: Novo Nordisk
• CSL300: CSL Behring
• Inclisiran: Novartis Pharmaceuticals
• Ertugliflozin: Merck Sharp & Dohme LLC
• Olpasiran: Amgen
• Olezarsen: Ionis Pharmaceuticals, Inc.
• Obicetrapib: NewAmsterdam Pharma
• Tetrahydrobiopterin: BioMarin Pharmaceutical
• MEDI6570: AstraZeneca
• GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.
Atherosclerosis Route of Administration
Atherosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type
Atherosclerosis Molecule Type
Atherosclerosis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Atherosclerosis Pipeline Therapeutics Assessment
• Atherosclerosis Assessment by Product Type
• Atherosclerosis By Stage and Product Type
• Atherosclerosis Assessment by Route of Administration
• Atherosclerosis By Stage and Route of Administration
• Atherosclerosis Assessment by Molecule Type
• Atherosclerosis by Stage and Molecule Type
DelveInsight's Atherosclerosis Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Atherosclerosis product details are provided in the report. Download the Atherosclerosis pipeline report to learn more about the emerging Atherosclerosis therapies
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Atherosclerosis Therapeutics Market include:
Key companies developing therapies for Atherosclerosis are - SL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others.
Atherosclerosis Pipeline Analysis:
The Atherosclerosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atherosclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atherosclerosis Treatment.
• Atherosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atherosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atherosclerosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Atherosclerosis drugs and therapies
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Atherosclerosis Pipeline Market Drivers
• Rising prevalence of cardiovascular diseases, growing number of geriatric population, increase in the number of research and development activities are some of the important factors that are fueling the Atherosclerosis Market.
Atherosclerosis Pipeline Market Barriers
• However, high cost associated with the treatment, lack of awareness among people and other factors are creating obstacles in the Atherosclerosis Market growth.
Scope of Atherosclerosis Pipeline Drug Insight
• Coverage: Global
• Key Atherosclerosis Companies: ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, CSL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerosis Therapies: TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• Atherosclerosis Therapeutic Assessment: Atherosclerosis current marketed and Atherosclerosis emerging therapies
• Atherosclerosis Market Dynamics: Atherosclerosis market drivers and Atherosclerosis market barriers
Request for Sample PDF Report for Atherosclerosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Atherosclerosis Report Introduction
2. Atherosclerosis Executive Summary
3. Atherosclerosis Overview
4. Atherosclerosis- Analytical Perspective In-depth Commercial Assessment
5. Atherosclerosis Pipeline Therapeutics
6. Atherosclerosis Late Stage Products (Phase II/III)
7. Atherosclerosis Mid Stage Products (Phase II)
8. Atherosclerosis Early Stage Products (Phase I)
9. Atherosclerosis Preclinical Stage Products
10. Atherosclerosis Therapeutics Assessment
11. Atherosclerosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atherosclerosis Key Companies
14. Atherosclerosis Key Products
15. Atherosclerosis Unmet Needs
16 . Atherosclerosis Market Drivers and Barriers
17. Atherosclerosis Future Perspectives and Conclusion
18. Atherosclerosis Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports by DelveInsight
• Addison's Disease Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Cardiac Monitoring System Market: https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
• Medical Sterilization Equipment Market: https://www.delveinsight.com/report-store/medical-sterilization-equipment-market
• Tinnitus Market: https://www.delveinsight.com/report-store/tinnitus-medical-devices-market
• Vutrisiran Market: https://www.delveinsight.com/report-store/vutrisiran-market
• Microscopy Device Market: https://www.delveinsight.com/report-store/microscopy-device-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atherosclerosis Pipeline Assessment 2024: Therapies, Clinical Trials, and Emerging Therapies by DelveInsight | Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen here
News-ID: 3762556 • Views: …
More Releases from DelveIinsight Business Research
Thymidine Kinase 2 Deficiency Market Insights: Unmet Needs and Emerging Therapie …
The Thymidine Kinase 2 deficiency (TK2d) market is poised for substantial growth in the coming decade, fueled by increasing awareness of this rare genetic disorder and the development of promising therapies like MT1621 (UCB).
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers comprehensive insights into the current TK2d landscape and future market trends across the 7MM (United States, EU4, the United Kingdom, and Japan).…
Pigment Epithelial Detachment Market Outlook: Aging Population, AI-Driven Diagno …
Recent analysis by DelveInsight indicates that the retinal pigment epithelium market is poised for notable growth, with the 7MM expected to achieve a respectable CAGR. This growth is being fueled by several factors, including an aging population, advancements in AI-driven diagnosis, industry collaborations, and novel therapeutic options. Key retinal pigment epithelium companies include Sumitomo Pharma, Healios K.K., Eyestem Research, Luxa Biotechnology, Regenerative Patch Technologies, Lineage Cell Therapeutics, Katairo GmbH, Visgenx…
Chronic Obstructive Pulmonary Disease Market Forecast 2024-2034: Competitive Int …
The chronic obstructive pulmonary disease (COPD) market is projected to experience steady growth in the coming years, driven primarily by increasing diagnosed prevalent cases and the introduction of novel biologics and combination therapies by key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Amgen, among others. This market expansion reflects advancements in targeted therapeutic approaches, particularly for patients with specific phenotypes, improved diagnostic capabilities, and rising awareness among healthcare…
Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Landscape Transforms with …
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market across the 7MM is poised for significant growth through 2034. This growth is driven by advancements in targeted therapies, increased awareness of the disease among healthcare professionals, and ongoing research and development efforts. Major pharmaceutical and biotech companies, including AbbVie, ImmunoGen, Mustang Bio, Genentech, Stemline Therapeutics, Jazz Pharmaceuticals, Menarini Group, Cellex Patient Treatment GmbH, and Xencor, are actively engaged in the BPDCN…
More Releases for Atherosclerosis
Leading Growth Driver in the Atherosclerosis Drugs Market in 2025: Atheroscleros …
Which drivers are expected to have the greatest impact on the over the atherosclerosis drugs market's growth?
The anticipated growth of the atherosclerosis drug market is likely due to the increased prevalence of cardiovascular diseases. These ailments usually impact the heart and blood vessels, and atherosclerosis, a condition arising from the accumulation of fats, cholesterol, and other substances on one's artery walls, is usually responsible. Key complications of atherosclerosis include coronary…
Atherosclerosis Therapeutics Market Projected to Show Strong Growth
The "Atherosclerosis Therapeutics Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. to determine market size, potential, growth trends, and competitive environment, the Atherosclerosis Therapeutics Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured…
Atherosclerosis Drugs Market Size 2024 to 2031.
Market Overview and Report Coverage
Atherosclerosis is a condition characterized by the buildup of plaque in the arteries, leading to restricted blood flow and an increased risk of heart attack or stroke. Atherosclerosis drugs are medications used to manage the symptoms and complications of this condition.
The Atherosclerosis Drugs Market is expected to grow at a CAGR of 4.00% during the forecasted period. The increasing prevalence of lifestyle-related diseases such…
Atherosclerosis Therapeutics Market: Competitive Dynamics & Global Outlook 2024
LP INFORMATION offers a latest published report on Atherosclerosis Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Atherosclerosis Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,…
Atherosclerosis Therapeutics Market: Competitive Dynamics & Global Outlook 2025
Market Research Report Store offers a latest published report on Atherosclerosis Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This report focuses on the key global Atherosclerosis Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Atherosclerosis Therapeutics with respect to individual growth…
Atherosclerosis Market Revenue and Value Chain 2016-2026
Atherosclerosis is the narrowing of the vein as a result of plaque build-up. Atherosclerosis is a particular kind of arteriosclerosis (stiffening or solidifying of the artery walls). The illness disturbs the stream of blood around the body, posturing genuine cardiovascular entanglements. Atherosclerosis begins when the endothelium gets to be harmed, permitting LDL cholesterol to aggregate in the artery wall. The body sends macrophage white platelets to tidy up the cholesterol.…
